Empagliflozin in the Treatment of Heart Failure and Type 2 Diabetes Mellitus: Evidence from Several Large Clinical Trials

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2022 Aug 3

PMID 35919809

Authors

Bo Liang

Ning Gu

Affiliations

Soon will be listed here.

Abstract

Heart failure coexists with type 2 diabetes mellitus, which seriously affects the clinical treatment and prognosis. At present, the treatment for patients with established heart failure and type 2 diabetes mellitus is usually combined with two treatment strategies for heart failure and type 2 diabetes mellitus. Recently, increasing studies showed that empagliflozin, a sodium-glucose co-transporter-2 inhibitor, has a positive effect on the treatment of patients with established heart failure and type 2 diabetes mellitus. Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations.

Citing Articles

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.

Frak W, Hajdys J, Radzioch E, Szlagor M, Mlynarska E, Rysz J Biomedicines. 2023; 11(7).

PMID: 37509724 PMC: 10377079. DOI: 10.3390/biomedicines11072085.

Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events.

Towiargi R, Fetyani L, Aljahdali N, Alnofeie A, AlNoamy Y, Ghandorah R Cureus. 2023; 14(12):e33070.

PMID: 36721538 PMC: 9883530. DOI: 10.7759/cureus.33070.

Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.

Liang B, Li R, Zhang P, Gu N J Cardiovasc Transl Res. 2022; 16(2):327-340.

PMID: 35969357 DOI: 10.1007/s12265-022-10302-4.

References

Butler J, Filippatos G, Siddiqi T, Brueckmann M, Bohm M, Chopra V . Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation. 2021; 145(3):184-193. PMC: 8763045. DOI: 10.1161/CIRCULATIONAHA.121.057812. View

Pasternak B, Ueda P, Eliasson B, Svensson A, Franzen S, Gudbjornsdottir S . Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019; 366:l4772. PMC: 6713906. DOI: 10.1136/bmj.l4772. View

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Jankauskas S, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A . Heart failure in diabetes. Metabolism. 2021; 125:154910. PMC: 8941799. DOI: 10.1016/j.metabol.2021.154910. View

Seferovic P, Petrie M, Filippatos G, Anker S, Rosano G, Bauersachs J . Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(5):853-872. DOI: 10.1002/ejhf.1170. View

Tanaka H, Tatsumi K, Matsuzoe H, Matsumoto K, Hirata K . Impact of diabetes mellitus on left ventricular longitudinal function of patients with non-ischemic dilated cardiomyopathy. Cardiovasc Diabetol. 2020; 19(1):84. PMC: 7293795. DOI: 10.1186/s12933-020-01063-y. View

Hias J, Hellemans L, Walgraeve K, Tournoy J, Van der Linden L . SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Drugs Aging. 2022; 39(3):185-190. DOI: 10.1007/s40266-022-00920-7. View

Patorno E, Pawar A, Franklin J, NajafZadeh M, Deruaz-Luyet A, Brodovicz K . Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019; 139(25):2822-2830. PMC: 6594384. DOI: 10.1161/CIRCULATIONAHA.118.039177. View

Liang B, Zhao Y, Gu N . Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions. Cardiovasc Diabetol. 2020; 19(1):29. PMC: 7063753. DOI: 10.1186/s12933-020-01004-9. View

10.

Seferovic P, Coats A, Ponikowski P, Filippatos G, Huelsmann M, Jhund P . European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2019; 22(2):196-213. DOI: 10.1002/ejhf.1673. View

11.

Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I . Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovasc Diabetol. 2021; 20(1):105. PMC: 8237440. DOI: 10.1186/s12933-021-01295-6. View

12.

Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

13.

Requena-Ibanez J, Santos-Gallego C, Rodriguez-Cordero A, Vargas-Delgado A, Mancini D, Sartori S . Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021; 9(8):578-589. DOI: 10.1016/j.jchf.2021.04.014. View

14.

Kosiborod M, Lam C, Kohsaka S, Kim D, Karasik A, Shaw J . Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018; 71(23):2628-2639. DOI: 10.1016/j.jacc.2018.03.009. View

15.

Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino M, Esposito K . SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021; 20(1):236. PMC: 8680308. DOI: 10.1186/s12933-021-01430-3. View

16.

MacDonald M, Petrie M, Varyani F, Ostergren J, Michelson E, Young J . Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29(11):1377-85. DOI: 10.1093/eurheartj/ehn153. View

17.

Butler J, Packer M, Filippatos G, Ferreira J, Zeller C, Schnee J . Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2021; 43(5):416-426. PMC: 8825259. DOI: 10.1093/eurheartj/ehab798. View

18.

McHugh K, DeVore A, Wu J, Matsouaka R, Fonarow G, Heidenreich P . Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(5):602-611. DOI: 10.1016/j.jacc.2018.11.033. View

19.

Schork A, Saynisch J, Vosseler A, Jaghutriz B, Heyne N, Peter A . Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019; 18(1):46. PMC: 6451223. DOI: 10.1186/s12933-019-0852-y. View

20.

Thomsen R, Knudsen J, Kahlert J, Baggesen L, Lajer M, Holmgaard P . Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. J Am Heart Assoc. 2021; 10(11):e019356. PMC: 8483550. DOI: 10.1161/JAHA.120.019356. View